LipoScience Inc, an in vitro diagnostic company advancing patient care by developing high-value proprietary clinical tests using nuclear magnetic resonance (NMR) technology, has launched Lipoprotein Perspectives, a medical education portal featuring experts in clinical and preventive cardiology, endocrinology, and lipidology. The Web site is designed as a vehicle for health care professionals to expand their knowledge about the role that lipoprotein particles play in cardiovascular disease management.
“We expect that Lipoprotein Perspectives will become a destination Web site for clinicians who wish to better understand the role of lipoprotein particles in cardiovascular disease,” said James Underberg, MD, a New York-based practicing clinical lipidologist and specialist in cardiovascular disease prevention who serves as a contributor to the Web site. “We believe that the broad spectrum of informative and useful content should appeal to medical professionals across a wide variety of specialties, and this site will provide access to current information.”
Notable features of the new Web site include the Learning Center Library, which offers slide decks, video presentations, abstracts, and other documents; the e-Case Corner, which contains traditional case study resources and interactive scenarios about patients with Type 2 diabetes mellitus, family history of coronary artery disease, metabolic syndrome, and more; CVD Currents, a blog from experts on varying topics, including controversies in lipid management and updates on late-breaking research; and a section devoted to conferences, webinars, and other educational programs and events.
“Lipoprotein Perspectives was created to provide a comprehensive resource about the role of lipoprotein particles in atherogenesis, cardiovascular disease progression and clinical management,” said Robert Honigberg, MD, Chief Medical Officer and Vice President, Medical Affairs of LipoScience. “It is our hope to offer insight into overcoming the challenges of managing patients to reduce and eliminate residual cardiovascular risk.”
Source: LipoScience Inc
